UC San Diego Health Moores Cancer Center
@UCSDCancer
Followers
2K
Following
966
Media
752
Statuses
1K
NCI-designated & Comprehensive. Research, clinical trials, transformative care, survivorship, public-policy changing discoveries. #DeliveringDiscoveries
San Diego, California
Joined December 2021
Moores Member Sheri Hartman, PhD, published in JNCI Cancer Spectrum on a 12-month digital physical activity program for cancer survivors. Engaged participants saw improvements in peak step cadence and sit-to-stand performance. Read more: https://t.co/ACqITpMuyC
0
0
0
Moores Members Corina Antal, PhD, Susan Taylor, PhD, and Alexandra Newton, PhD publish in the Journal of Biological Chemistry a strategy to create pseudokinases that block ATP binding and reveal non-catalytic roles of PKC and Akt. Read more: https://t.co/rleGRawNWe
0
0
0
Moores Member Miguel Reina Campos, PhD joins “The Science Of” to discuss his path from Spain to the U.S., the power of tissue-resident memory T cells, how hormones shape immunity, and the future of personalized cancer immunotherapy. Listen: https://t.co/hDVQOyvXOv
0
0
1
A new study in Transplantation and Cellular Therapy from Moores Member Eric Anderson, MD, examines acute toxicities in tandem ASCT for pediatric high-risk neuroblastoma and identifies opportunities for earlier intervention. Read more: https://t.co/1kxcAvNwb5
0
0
0
New research from Moores Members Dennis A. Carson, MD and Karl Willert, PhD identifies FZD7 as a promising target for triple-negative breast cancer. Their antibody-drug conjugate reduced tumor growth in preclinical models with no observed toxicity. More: https://t.co/km87mtqt3u
0
0
0
Pancreatic cancer often develops without early symptoms. Knowing the risks and facts can save lives. 💜 #PancreaticCancerAwareness
0
0
0
Grateful for our community today and every day. Wishing you a warm Thanksgiving from Moores Cancer Center 🧡
0
0
1
Moores Members Jason Sicklick, MD and Shumei Kato, MD studied CD40 in 514 solid tumors. High CD40 in liver, pancreatic, and ovarian cancers co-expressed with CD28 and GITR, highlighting potential targets for next-gen immunotherapies. Read more: https://t.co/UL5sA7Q7P5
0
0
0
New Nature research from Moores Cancer Center Director Diane Simeone, MD shows lung tumors depend on FSP1 to evade ferroptosis. Blocking FSP1 restored ferroptosis and slowed tumor growth in preclinical models, highlighting a promising target. More: https://t.co/Pe2EITwtkH
0
0
0
Moores Cancer Center leaders share their insights on this year's Annual Scientific Retreat 🧬 Featuring: • Diane M. Simeone, MD • J. Silvio Gutkind, PhD • Rebecca Shatsky, MD • Trey Ideker, PhD • Elena Martinez, PhD Full recap below: https://t.co/KqR2oysJQm
0
2
3
Moores Members Alessandro Sette, PhD, Hannah Carter, PhD, MEng, Stephen Schoenberger, PhD, and Bjoern Peters, PhD led the largest meta-analysis of neo-epitopes to uncover insights that may strengthen cancer immunotherapy. More: https://t.co/t1vxG90m5e
0
0
1
Scientists, clinicians, trainees, and collaborators all came together for a full day of innovation at the Moores Cancer Center Annual Scientific Retreat 🧬 Learn more about it here: https://t.co/KqR2oysJQm
0
0
2
The Innovations in Oncology Clinical Trial Design symposium, hosted by UCSD Moores Cancer Center & Biocom California, showcased patient-centered trials, adaptive designs & AI tools speeding research & improving outcomes. Read more: https://t.co/4NCgR3xLJA
1
0
1
Researchers at the Moores Cancer Center Annual Scientific Retreat took on a challenge... and delivered 🧬 Featuring: • Ethan Tabibzadeh • Tasha Nguyễn • Sara Bernstein • Erin Yamaoka • Disha Surana Explore more highlights from the retreat: https://t.co/KqR2oysJQm
0
0
0
Moores Member Ludmil Alexandrov, PhD, reports in Cancer Discovery three transcriptomic subtypes of lung adenocarcinoma in never-smokers—Steady, Proliferative, Chaotic. A 60-gene signature predicts survival and aids early-stage NS-LUAD prognosis. Read more: https://t.co/Bo6EvZ0tK5
0
1
1
We are pleased to announce Bassel F. El-Rayes, MD, as the newest Deputy Director of Moores Cancer Center, effective February 1, 2026. A nationally recognized leader in GI oncology and translational research, we look forward to his leadership as we continue to drive progress.
0
0
0
Moores Members Christopher Glass, MD, PhD, and Nicole Coufal, MD, PhD, report in Nature Immunology that loss of MEF2C in human microglia causes hyperinflammation, phagocytic and lysosomal defects, and lipid buildup. Read more: https://t.co/xYRrNfOD4P
0
0
0
50 UC San Diego researchers, including many from Moores Cancer Center, are named among the world’s most influential on the 2025 Highly Cited Researchers list! Read more: https://t.co/tTL33bQlNs
0
0
0
UC San Diego researchers, including Moores Member Kelly A. Frazer, PhD, developed an AI model that predicts skin cancer risk using genetic, lifestyle, and social factors, improving early detection and reducing disparities. Read more: https://t.co/rz7t27y4UB
0
0
0
Moores member Raphael Cuomo, PhD, and colleagues found GLP-1 drugs like Ozempic may improve colon cancer outcomes. Published in Cancer Investigation, the study highlights a potential protective effect and calls for more research. Read more » https://t.co/y11beXxrPi
0
0
1